Use of bupivacaine liposomal injectable suspension in children aged 2 to 6 years undergoing cardiac surgery does not accelerate recovery

在2至6岁接受心脏手术的儿童中使用布比卡因脂质体注射混悬液并不能加速康复。

阅读:2

Abstract

OBJECTIVE: Bupivacaine liposomal injectable suspension is proven safe and effective for selective postsurgical analgesia in children older than 6 years. We evaluated if intraoperative bupivacaine liposomal injectable suspension administration decreases postoperative opioid use, peak pain scores, and length of stay in children aged 2 to 6 years undergoing cardiac surgery via median sternotomy. METHODS: Serial patients aged 2 to 6 years undergoing cardiac surgery received 4 mg/kg bupivacaine liposomal injectable suspension mixed with 0.25% bupivacaine hydrochloride and 0.9% sodium chloride via local infiltration at the conclusion of their procedure. They were matched with controls who underwent operation within the past 5 years by procedure, age, gender, and weight. Postoperative opioid use was converted into morphine milligram equivalents, and pain severity was measured using the Face, Legs, Activity, Cry, and Consolability scale. Paired t tests, chi-square tests, and descriptive statistics were used depending on the nature of the data. RESULTS: A total of 100 patients receiving bupivacaine liposomal injectable suspension and matching historical control patients aged 2 to 6 years were analyzed. There were no significant differences in preoperative variables. Patients receiving bupivacaine liposomal injectable suspension received an average of 3.6 (95% CI, 1.2-6.0) fewer morphine milligram equivalents (P = .003). However, there was no significant difference in peak pain score (P = .4), time to first enteral intake (P = .5), intensive care unit length of stay (P = 1), or hospital length of stay (P = .2). The median cost of bupivacaine liposomal injectable suspension was higher than that of bupivacaine hydrochloride (P < .001). CONCLUSIONS: Intraoperative bupivacaine liposomal injectable suspension use in children aged 2 to 6 years undergoing cardiac surgery showed statistically but not clinically significant decreases in postoperative opioid use. Bupivacaine liposomal injectable suspension use had no impact on intensive care unit or hospital length of stay but was substantially more expensive.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。